We use our own and third-party cookies to optimize your experience on this site, including to maintain user sessions. Without these cookies our site will not function well. If you continue browsing our site we take that to mean that you understand and accept how we use the cookies. If you wish to decline our cookies we will redirect you to Google.
Already have an account? Sign in.

 Remember Me | Forgot Your Password?

Three New Slimming Drugs Await US FDA Approval

April 13, 2010: 03:23 AM EST
The US Food and Drug Association is studying the effects of three new anti-obesity drugs before they can be sold in the market. Those awaiting regulatory approval are Lorcaserin from Arena Pharmaceuticals Inc., Qnexa from Vivus Inc. and Contrave from Orexigen Therapeutics Inc. Currently the FDA has approved just two anti-obesity drugs for long-term use – Meridia from Abbott Laboratories and Orlistat, which is sold over the counter as Alli by GlaxoSmithKline and in prescription form as Xenical by Roche Holding AG – but Meridia has been associated with heart complications and Orlistat with bowel-related problems. Also, neither has been a great success, Alli’s U.S. sales are estimated at $150 million, and Meridia’s and Xenical’s sales at just $40 million and $35 million, respectively. The new medications affect the patient’s central nervous system to dampen appetite could also have side effects for some patients but doctors said having various treatments could help them match a patient to a therapy that maximizes weight loss with fewer side effects.
THOMAS GRYTA , "Regulators to Review New Drugs to Curb Appetite", Wall Street Journal, April 13, 2010, © Dow Jones & Company, Inc
Diet Insights
Diet Research & Advice
Policy & Regulation
North America
United States of America
Legal, Legislation, Regulation, Policy
Products & Brands
Research, Studies, Advice
Developed by Yuri Ingultsov Software Lab.